People · Operator
Named in public records as an officer, director or promoter · active 2019–2022 · Biotechnology, Pharma, Biotech / Pharma
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Biolinq Inc | — | Biotechnology | Series C | $247.4M | $618.5M | 2021 |
| Bluejay Therapeutics, Inc. | — | Pharma | Series D+ | $221.7M | $2.1B | 2022 |
| Xilio Therapeutics, Inc. | — | Biotechnology | Series C | $145.2M | $3.0B | 2021 |
| Scout Bio, Inc. | — | Biotech / Pharma | Series B | $34.0M | $104.2M | 2019 |
Nancy Hong at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Nancy Hong on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| DAVID GARDNER | 1 | 20 |
| Michael Ross | 1 | 18 |
| Robert Weisskoff | 1 | 12 |
| Patrick Heron | 1 | 11 |
| Daniel Lynch | 1 | 7 |
| Daniel Bradbury | 1 | 7 |
| Alon Lazarus | 1 | 7 |
| David Grayzel | 1 | 6 |
| Andrew Hack | 1 | 5 |
| Zina Affas Besse | 1 | 4 |
| Dan Bradbury | 1 | 3 |
| Kevin Mahoney | 1 | 3 |
| Daniel Curran | 1 | 3 |
| Wen Chen | 1 | 3 |
| CHRIS DIMITROPOULOS | 1 | 3 |
| William J. Rutter | 1 | 3 |
| Dan Estes | 1 | 3 |
| RICHARD YANG | 1 | 2 |
| Rene Russo | 1 | 2 |
| Lana Ghanem | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.